Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma
NCT05923190Phase 2Active, not recruiting
- Sponsor
- Fox Chase Cancer Center
- Start
- Jun 2023
- Primary completion
- Jul 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of enfortumab vedotin in urothelial carcinoma (UC) (2 arms), sponsored by Fox Chase Cancer Center. Primary endpoint: Duration of clinical benefit at 8 months. Started Jun 2023; status: active, not recruiting.
02
Drugs
enfortumab vedotin
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT05923190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05923190.